Trial reportAntioxidants & redox signaling2014
NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q10.
Trial report in Antioxidants & redox signaling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Efficacy and safety of gabapentinoid combination therapy versus monotherapy for the treatment of neuropathic pain.Frontiers in physiology · 2026Pooled it
- Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.European journal of clinical pharmacology · 2022Trial
- Trial
- Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?Antioxidants & redox signaling · 2015Trial
- Next-Generation Adaptogens: Molecular Mechanisms, Bioactive Compounds and Human Health Relevance of Selected Botanicals and Fungi.International journal of molecular sciences · 2026Review
- Dimethyl Fumarate and Cobalt Protoporphyrin IX Inhibit Fibromyalgia-like Pain by Modulating Region-Specific Redox Pathways.Antioxidants (Basel, Switzerland) · 2026Article
- Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing.Inflammopharmacology · 2026Review
- Altered Circulating Biomarkers of Purinergic Signaling, Inflammasome-Related Pathways, Pyroptosis, and Oxidative Stress in Fibromyalgia.International journal of molecular sciences · 2026Article
- Microbiome-derived metabolites alleviate chronic pain in a reserpine-induced model of fibromyalgia.iScience · 2026Article
- Mitochondrial Dysfunctions in Human Primary Coenzyme QBiomolecules · 2026Review
- The Association Between miRNA-223-3p Levels and Pain Severity in Fibromyalgia Syndrome: A Molecular Approach.International journal of molecular sciences · 2025Article
- Dietary Phytonutrients in Fibromyalgia: Integrating Mechanisms, Biomarkers, and Clinical Evidence-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Endoplasmic reticulum stress and oxidative imbalance is the missing link in fibromyalgia pathophysiology.Scientific reports · 2025Article
- In Search of Molecular Correlates of Fibromyalgia: The Quest for Objective Diagnosis and Effective Treatments.International journal of molecular sciences · 2025Review
- Possible Interaction of Suramin with Thalamic P2X Receptors and NLRP3 Inflammasome Activation Alleviates Reserpine-Induced Fibromyalgia-Like Symptoms.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- MCC950 Reduces the Anxiodepressive-like Behaviors and Memory Deficits Related to Paclitaxel-Induced Peripheral Neuropathy in Mice.Antioxidants (Basel, Switzerland) · 2025Article
- Review
- Development and Characterization ofAntioxidants (Basel, Switzerland) · 2023Article
- Melatonin as a Coadjuvant in the Treatment of Patients with Fibromyalgia.Biomedicines · 2023Review
- Delivery of coenzyme Q10 loaded micelle targets mitochondrial ROS and enhances efficiency of mesenchymal stem cell therapy in intervertebral disc degeneration.Bioactive materials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsFibromyalgia (FM) is a prevalent chronic pain syndrome characterized by generalized hyperalgesia associated with a wide spectrum of symptoms such as fatigue and joint stiffness. Diagnosis of FM is difficult due to the lack of reliable diagnostic biomarkers, while treatment is largely inadequate. We have investigated the role of coenzyme Q10 (CoQ10) deficiency and mitochondrial dysfunction in inflammasome activation in blood cells from FM patients, and in vitro and in vivo CoQ10 deficiency models.
resultsMitochondrial dysfunction was accompanied by increased protein expression of interleukin (IL)-1β, NLRP3 (NOD-like receptor family, pyrin domain containing 3) and caspase-1 activation, and an increase of serum levels of proinflammatory cytokines (IL-1β and IL-18). CoQ10 deficiency induced by p-aminobenzoate treatment in blood mononuclear cells and mice showed NLRP3 inflammasome activation with marked algesia. A placebo-controlled trial of CoQ10 in FM patients has shown a reduced NLRP3 inflammasome activation and IL-1β and IL-18 serum levels. INNOVATION: These results show an important role for the NLRP3 inflammasome in the pathogenesis of FM, and the capacity of CoQ10 in the control of inflammasome.
conclusionThese findings provide new insights into the pathogenesis of FM and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.